Bryan Zerhusen, Partner in Locke Lord’s Intellectual Property group, represented Arvinas LLC, a private biopharmaceutical company creating a new class of drugs based on targeted protein degradation, in IP due diligence as part of its Series B financing round of $41.6 million. All of the initial Series A investors, including the two lead Series A investors, Canaan Partners and 5AM Ventures, participated in this new round. In addition, three leading private venture investment firms joined the round: RA Capital Management, OrbiMed and New Leaf Venture Partners. Zerhusen has managed Arvinas's IP portfolio since the company’s inception and supported the IP due diligence during all of the financing rounds.
Posted October 26, 2015